Two Institutions Publish Independent Data on Novocure’s Tumor Treating Fields
Publications represent growing interest from scientific community in Novocure’s broadly applicable mechanism of action
ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that two independent institutions published scientific research on Tumor Treating Fields (TTFields), representing increasing external interest from the scientific community in Novocure’s innovative, proprietary therapy. The published data support Novocure’s existing body of research establishing TTFields as a low-toxicity, effective cancer treatment while adding new insights to the mechanism of action beyond the known anti-mitotic properties of this modality. The following articles were published:
- Kim et al. “Biological effect of an alternating electric field on cell proliferation and synergistic antimitotic effect in combination with ionizing radiation.” Oncotarget, Aug. 19, 2016; Korea Institute of Radiological & Medical Sciences and Department of Bio-Convergence Engineering, Korea University
- Kim et al. “Tumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesis.” Oncotarget, Aug. 18, 2016; Korea Institute of Radiological & Medical Sciences and Department of Bio-Convergence Engineering, Korea University
- Pavesi et al. “Engineering a 3D microfluidic culture platform for tumor-treating field application.” Scientific Reports, May 24, 2016; Singapore–MIT Alliance for Research and Technology, BioSystems
“We have been interested in learning more about Novocure’s treatment with TTFields for some time and were eager to conduct our own research,” said Myonggeun Yoon, a Professor at the School of Biomedical Engineering, Korea University. “TTFields is a promising, novel cancer treatment with broad applicability, and we look forward to seeing how the research on TTFields will evolve.”
“Based on the growing interest in TTFields, we decided to develop a microfluidic system that can be used to rapidly screen the effect of this emerging modality on both cancer and normal cells within an in vivo like microenvironment,” said Dr. Andrea Pavesi, a research scientist from the Singapore–MIT Alliance for Research and Technology (SMART). “Indeed, using our novel device, we were able to demonstrate that TTFields application selectively targeted cancer cells while minimally affecting endothelial cells,” added Dr. Giulia Adriani, also research scientist at SMART.
Internationally, over 20 institutions are studying TTFields, including 10 that are using Novocure’s inovitro system, a lab research tool that allows investigators to efficiently study the effects of different field parameters and TTFields’ synergies with various drug and radiation combinations.
“We are excited that an increasing number of independent institutions are studying TTFields and supplementing the research we have conducted thus far,” said Dr. Eilon Kirson, Chief Science Officer and Head of Research and Development at Novocure. “We believe greater interest in TTFields from the scientific community will help us raise awareness of our innovative cancer therapy.”
Novocure is a commercial-stage oncology company developing a proprietary therapy called Tumor Treating Fields, or TTFields, for the treatment of solid tumor cancers. Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania, and New York City. Additionally, the company has offices in Germany, Switzerland and Japan, and a research center in Haifa, Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on March 1, 2016, with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.
Media and Investor Contact:
Ashley Cordova, 212-767-7558